Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Profit After Tax (2016 - 2025)

Altimmune (ALT) has disclosed Profit After Tax for 16 consecutive years, with -$19.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Profit After Tax rose 16.77% to -$19.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$83.9 million, a 18.94% increase, with the full-year FY2024 number at -$95.1 million, down 7.48% from a year prior.
  • Profit After Tax was -$19.0 million for Q3 2025 at Altimmune, up from -$22.1 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$14.9 million in Q1 2021 to a low of -$33.5 million in Q3 2021.
  • A 5-year average of -$22.4 million and a median of -$22.1 million in 2025 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: crashed 282.54% in 2021, then grew 29.82% in 2022.
  • Altimmune's Profit After Tax stood at -$23.9 million in 2021, then rose by 9.33% to -$21.7 million in 2022, then plummeted by 46.08% to -$31.6 million in 2023, then rose by 26.74% to -$23.2 million in 2024, then rose by 17.97% to -$19.0 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Profit After Tax are -$19.0 million (Q3 2025), -$22.1 million (Q2 2025), and -$19.6 million (Q1 2025).